Columbia Med. Professor Tied To Hedge Fund Insider-Trading Case

Sep 19 2011 | 4:40am ET

A Columbia University medical professor is alleged to have passed confidential information about a drug trial to a Cambridge, Mass., hedge fund.

Andrew Bomback is the tipster identified as “Doctor 1” in Massachusetts’ civil lawsuit against Risk Reward Capital and its founder, James Silverman, The New York Times reports. The Gray Lady was able to determine Bomback’s identity by comparing the lawsuit and a press release from one of the companies that Silverman is accused of trading illegally, Questcor Pharmaceuticals.

“I’m actually surprised you were able to identify me,” Bomback, who is a consultant for Questcor, told the Times. But he admitted that he is “Doctor 1.”

Bomback is not accused of any wrongdoing by Massachusetts regulators, and denies breaking the law, as does Silverman.

“Mr. Silverman has never received any material, non-public information from me,” he told the Times.

Massachusetts begs to differ: It say that Risk Reward’s performance turned around once it began working with expert-network Guidepoint Global. Guidepoint put Silverman in touch with Bomback, who probably knew more about Questcor’s only drug than any other person, having reviewed all 21 of the patient files from the test—eight of the patients were his own.

Bomback said he only spoke with Silverman about his patients. But Silverman’s notes, turned over to the authorities as part of the investigation, show that the two actually discussed all 21 cases.

The case has led Massachusetts to impose new rules covering expert networks.


In Depth

GSAM's Papagiannis: Liquid Alternatives For The Long Run

Apr 21 2017 | 8:44pm ET

Interest in liquid alternatives cooled a bit last year amid a broad shift in investor...

Lifestyle

Aston Martin Returns To Debt Market As DB11 Drives Turnaround

Mar 31 2017 | 5:21pm ET

James Bond’s preferred carmaker is returning to the public debt markets for the...

Guest Contributor

Debunking Conventional Investment Wisdom (Part II)

Apr 17 2017 | 5:56pm ET

The alternative investment industry is currently replete with buzzwords around data...

 

From the current issue of